MedPath

EuMelaReg gGmbH

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC

Recruiting
Conditions
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
First Posted Date
2023-02-23
Last Posted Date
2025-03-12
Lead Sponsor
EuMelaReg gGmbH
Target Recruit Count
1300
Registration Number
NCT05741073
Locations
🇧🇪

UZ (Universitair Ziekenhuis) Brüssel, Brussels, Belgium

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Completed
Conditions
Melanoma
First Posted Date
2019-05-09
Last Posted Date
2025-03-12
Lead Sponsor
EuMelaReg gGmbH
Target Recruit Count
232
Registration Number
NCT03944356
Locations
🇩🇪

Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude, Niedersachsen, Germany

🇩🇪

Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Nordrhein-Westfalen, Germany

🇩🇪

Universitätsklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie, Kiel, Schleswig-Holstein, Germany

and more 33 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.